Daily Cardiology Research Analysis
Three high-impact cardiology studies stood out today: a double-blind multicenter RCT showed AI-guided substrate ablation plus PVI is superior to PVI alone for persistent AF at 12 months; mechanistic work identified TRPM7 chanzyme activity in vascular smooth muscle cells as a driver of abdominal aortic aneurysm in mice; and a real-world comparative study found CMR has substantially higher diagnostic yield than bone scintigraphy across cardiac amyloidosis subtypes.
Summary
Three high-impact cardiology studies stood out today: a double-blind multicenter RCT showed AI-guided substrate ablation plus PVI is superior to PVI alone for persistent AF at 12 months; mechanistic work identified TRPM7 chanzyme activity in vascular smooth muscle cells as a driver of abdominal aortic aneurysm in mice; and a real-world comparative study found CMR has substantially higher diagnostic yield than bone scintigraphy across cardiac amyloidosis subtypes.
Research Themes
- AI-guided electrophysiology and precision ablation
- Ion channel–driven vascular remodeling mechanisms in aneurysm
- Imaging strategies for systemic amyloidosis involving the heart
Selected Articles
1. Artificial intelligence for individualized treatment of persistent atrial fibrillation: a randomized controlled trial.
In a multicenter double-blind RCT (n=370), AI-guided targeting of spatio-temporal dispersion areas in addition to PVI achieved higher 12-month AF freedom (88% vs 70%) than PVI alone after a single procedure, with similar safety but longer procedure times. Freedom from any atrial arrhythmia was not different, suggesting subsequent organized atrial tachycardias may arise.
Impact: This trial provides high-level evidence that AI-guided substrate mapping can improve outcomes in persistent AF beyond standard PVI, potentially redefining ablation strategy.
Clinical Implications: AI-guided dispersion mapping may be adopted as an adjunct to PVI for persistent AF in experienced centers, balancing improved AF freedom against longer procedures and planning for potential post-ablation atrial tachycardias.
Key Findings
- AI-guided tailored ablation plus PVI achieved 88% AF freedom at 12 months vs 70% with PVI alone (superiority; log-rank P<0.0001).
- No difference in freedom from any atrial arrhythmia after one ablation, implying subsequent organized atrial tachycardias.
- Safety outcomes were similar between arms, but procedure and ablation times were approximately doubled in the AI-tailored arm.
Methodological Strengths
- Multicenter, randomized, controlled, double-blind design with clear primary endpoint
- Head-to-head comparison of AI-guided tailored ablation versus standard PVI-only
Limitations
- Single-procedure 12-month follow-up; longer-term durability and repeat procedures not assessed
- Longer procedure times in AI arm and no difference in any atrial arrhythmia freedom
Future Directions: Evaluate long-term durability, impact on organized atrial tachycardias, cost-effectiveness, and generalizability across centers and operators; integration with other mapping modalities.
Although pulmonary vein isolation (PVI) has become the cornerstone ablation procedure for atrial fibrillation (AF), the optimal ablation procedure for persistent and long-standing persistent AF remains elusive. Targeting spatio-temporal electrogram dispersion in a tailored procedure has been suggested as a potentially beneficial alternative to a conventional PVI-only procedure. In this multicenter, randomized, controlled, double-blind, superiority trial, patients with drug-refractory persistent AF were randomly assigned to a tailored ablation procedure targeting areas of spatio-temporal dispersion, as detected by an artificial intelligence (AI) algorithm, in addition to PVI (tailored arm, n = 187, 23% women) or to a conventional PVI-only procedure (anatomical arm, n = 183, 19% women). The primary efficacy endpoint was freedom from documented AF with or without antiarrhythmic drugs at 12 months after a single ablation procedure. Secondary endpoints included freedom from any atrial arrhythmic events, and the secondary composite safety endpoint consisted of death, cerebrovascular events, or treatment-related serious adverse events. One year post-procedure, the trial met its primary efficacy endpoint, which was achieved in 88% of patients in the tailored arm compared with 70% of patients in the anatomical arm (log-rank P < 0.0001 for superiority). However, no significant difference between arms was observed for the freedom from any atrial arrhythmia endpoint after one ablation. The safety endpoint did not differ between arms, with procedure and ablation times being twice as long in the tailored arm. These results show that AI-guided ablation of spatio-temporal dispersion areas in addition to PVI is superior to PVI alone in eliminating AF at 1-year follow-up in patients with persistent and long-standing persistent AF. Ablation of subsequent organized atrial tachycardias may be needed to maintain sinus rhythm long term. ClinicalTrials.gov identifier: NCT04702451 .
2. The TRPM7 chanzyme in smooth muscle cells drives abdominal aortic aneurysm in mice.
Using cell type–specific knockouts across two AAA mouse models, the study shows that TRPM7 chanzyme activity in vascular smooth muscle cells drives aneurysm formation, promoting VSMC phenotypic switching, inflammation, and matrix degradation. SMC-specific Trpm7 deletion was protective, nominating TRPM7 as a therapeutic target.
Impact: Identifying TRPM7 as a cell-intrinsic driver of AAA provides a mechanistic foundation and a potentially druggable target for a disease lacking medical therapy.
Clinical Implications: While preclinical, targeting TRPM7 activity in VSMCs could emerge as a disease-modifying approach to slow or prevent AAA growth pending safety and translational studies.
Key Findings
- SMC-specific Trpm7 knockout protected mice from AAA in two distinct preclinical models.
- TRPM7 channel activity promoted Ca2+-dependent signaling, VSMC reprogramming, inflammation, and extracellular matrix degradation.
- Cell type–specific comparisons showed the pathogenic role was specific to smooth muscle cells, not macrophages or endothelial cells.
Methodological Strengths
- Use of multiple preclinical AAA models with cell type–specific genetic knockouts
- Convergent mechanistic analyses linking ion channel activity to phenotypic switching and matrix remodeling
Limitations
- Preclinical mouse models; human validation and safety of TRPM7 modulation are unknown
- Potential off-target effects of TRPM7 inhibition and systemic consequences were not addressed
Future Directions: Validate TRPM7 pathways in human AAA tissues, develop selective modulators, assess pharmacodynamics and safety, and test efficacy in large-animal models.
Ionic signaling in smooth muscle cells (SMCs) is critical for vascular homeostasis. In this study, we untangled the role of the bifunctional TRPM7 channel kinase (chanzyme) in abdominal aortic aneurysm (AAA) pathogenesis. Comparing SMC-specific, macrophage-specific and endothelial cell-specific Trpm7 knockout, we revealed that SMC-specific Trpm7 deficiency protected mice from AAA in two distinct preclinical models of the disease. We showed that the TRPM7 channel activity increased the Ca
3. Diagnostic value of bone scintigraphy versus cardiovascular magnetic resonance in cardiac amyloidosis.
In 123 patients who underwent both tests, CMR achieved 98.4% sensitivity for any cardiac amyloidosis versus 85.4% for bone scintigraphy, correctly identifying AL and ATTR cases when bone scintigraphy was negative or inconclusive. When CMR is clearly positive for CA, bone scintigraphy adds little diagnostic value.
Impact: The study challenges reliance on bone scintigraphy alone and supports CMR as a high-yield modality across amyloid subtypes, informing diagnostic pathways.
Clinical Implications: In suspected cardiac amyloidosis, early CMR can streamline diagnosis across subtypes (ATTR and AL). When CMR is unequivocally positive, bone scintigraphy may be unnecessary; however, monoclonal protein studies and biopsy remain crucial for AL confirmation.
Key Findings
- CMR sensitivity for any cardiac amyloidosis was 98.4% (121/123), outperforming bone scintigraphy at 85.4%.
- In 20 diagnostic mismatches, CMR correctly identified CA in 18 cases where bone scintigraphy was negative or inconclusive (including 8 AL-CM and 8 ATTR-CM).
- Overall agreement between modalities was 84%, but CMR provided higher yield across amyloid subtypes, not limited to ATTR-CM.
Methodological Strengths
- Head-to-head comparison of CMR and bone scintigraphy within the same real-world cohort
- Use of monoclonal protein studies and EMB for definitive diagnosis where needed
Limitations
- Single-center retrospective design with inclusion limited to patients having at least one positive imaging test, introducing selection bias
- Sample size is modest and generalizability across centers and protocols may vary
Future Directions: Prospective multicenter studies to validate diagnostic pathways integrating CMR with protein studies, and evaluation of cost-effectiveness and impact on time-to-diagnosis and therapy initiation.
BACKGROUND: Accurate diagnosis of transthyretin amyloidosis cardiomyopathy (ATTR-CM) and its differentiation from light-chain (AL) cardiac amyloidosis (CA) cases (AL-CM) are of paramount importance. Surprisingly, comparative imaging data based on concurrent cardiovascular magnetic resonance (CMR) and bone scintigraphy in the same patients with biopsy-proven diagnosis of CA are still rare. METHODS: This was a real-world retrospective single-center study based on a local clinical care pipeline and we carefully analyzed clinical, laboratory, CMR, and bone scintigraphy data (and if necessary additional endomyocardial biopsy [EMB] data) in patients with suspected CA. As a major inclusion criterion, we only looked at those patients who underwent both a CMR study and a bone scintigraphy-with a clear-cut imaging finding detected by at least one imaging method. RESULTS: One hundred twenty three patients in whom the final diagnosis was obtained either non-invasively based on combined findings from bone scintigraphy and monoclonal protein studies or invasively based on additional EMB findings were included. A positive CMR result indicating the presence of CA was found in 121 patients-suggesting a CMR sensitivity of 98.4% for the diagnosis of any CA. Bone scintigraphy identified 18 patients with low to moderate uptake (Perugini score = 0-1) and 105 patients with high uptake (Perugini score ≥2)-resulting in a sensitivity for bone scintigraphy of 85.4% for the diagnosis of any CA. There was an agreement ("diagnostic match") between CMR and bone scintigraphy results in 103 patients (84%) of the total study cohort, while a discrepancy ("diagnostic mismatch") was observed in 20 patients (16%). In 18 out of these 20 diagnostic mismatch cases, CMR correctly diagnosed the presence of CA despite a negative or inconclusive result on bone scintigraphy (8 with AL-CM, 8 with ATTR-CM, and 2 with EMB-proven but unspecified CA). CONCLUSION: CMR shows a substantially higher diagnostic yield for the diagnosis of CA compared to bone scintigraphy, if a real-world cohort of patients comprising different subtypes of CA is looked at, since CMR does not only detect ATTR-CM but also depicts other CA subtypes such as AL. In case of a clear-cut positive CMR result unequivocally indicative of CA, there is no incremental diagnostic value of an additionally performed bone scintigraphy.